Galderma announces interim data from two ongoing investigator-initiated trials highlight the role of Sculptra and Restylane in addressing aesthetic changes associated with weight loss medications and menopause (CHF 156.60, 0.00)
Galderma Group announces new phase II data on nemolizumab which demonstrates clinically meaningful benefits for children aged 2 to 11 with moderate-to-severe atopic dermatitis (CHF 149.60, 0.00)
StreetAccount Summary - European pre-market trading update
Galderma Group resumed buy at Citi (CHF 143.50, 0.00)
Galderma Group to present latest updates on its innovations across its portfolio at 2026 American Academy of Dermatology Annual Meeting, March 27-31 in Denver, Colorado (CHF 142.50, 0.00)
Galderma receives US FDA approval for Restylane Contour for the correction of temple hollowing (CHF 142.10, 0.00)
Galderma Group initiated outperform at Oddo (CHF 142.60, 0.00)
EQT AB confirms it completes final sell-down in Galderma (CHF 143.80, 0.00)
CORRECTION: Galderma repurchases 1.6M shares at a price of CHF 143.75/each from holders (CHF 154.60, 0.00)
Powered by FactSet Research Systems Inc.